Journal article
Clinical utility of quantifying hepatitis B surface antigen in African patients with chronic hepatitis B
G Post, J Howell, A Sow, G Ndow, I Chemin, G Lo, A Cessay, D Cohen, R Njie, S Toure, M Diop, R Sombie, J Nana, V Leroy, K Lacombe, L Bojang, F Tacke, C Toure-Kane, M Ka, M Mendy Show all
Journal of Viral Hepatitis | WILEY | Published : 2021
DOI: 10.1111/jvh.13499
Abstract
The clinical utility of quantifying hepatitis B surface antigen (qHBsAg) levels in African subjects with chronic hepatitis B virus (HBV) infection has been poorly documented. From a multicentre cohort of 944 HBV-infected African patients, we aimed to assess whether qHBsAg alone can accurately identify i) those in a HBeAg-negative chronic HBV infection phase at low risk of liver disease progression and ii) those in need of antiviral therapy according to the 2017 EASL guidelines. We analysed 770 HBV mono-infected treatment-naïve patients, mainly males (61%) from West Africa (92%), median age 35 years (IQR: 30–44), median HBV DNA: 95.6 IU/ml (10.0–1,300.0), median qHBsAg 5,498 IU/ml (1,171–13,0..
View full abstractGrants
Awarded by Gilead UK and Ireland Corporate Contributions
Funding Acknowledgements
The PROLIFICA project (www.proli fica.africa) was funded was the EC FP7 (2011--2016) and is currently funded by the MRC UK and received support from Gilead US company. The authors thank Echosens, France, for their support; they are also grateful to all the patients and their families.